MARKET

ZIOP

ZIOP

ZIOPHARM Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.820
0.000
0.00%
Pre Market: 1.900 +0.08 +4.40% 05:36 09/21 EDT
OPEN
1.760
PREV CLOSE
1.820
HIGH
1.910
LOW
1.740
VOLUME
6
TURNOVER
--
52 WEEK HIGH
5.95
52 WEEK LOW
1.260
MARKET CAP
392.32M
P/E (TTM)
-4.4521
1D
5D
1M
3M
1Y
5Y
30 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kadmon Holdings, Inc. (NASDAQ: KDMN) shares jumped 72.6% to $9.15. Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon in a $1.9 billion all-cash deal. Arqit Quantum Inc. (NASDAQ: ARQQ) gained 38% to $15.55 after jum...
Benzinga · 09/08 16:02
Is the Options Market Predicting a Spike ZIOPHARM (ZIOP) Stock?
Investors need to pay close attention to ZIOPHARM (ZIOP) stock based on the movements in the options market lately.
Zacks · 09/08 12:32
72 Biggest Movers From Yesterday
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Benzinga · 09/08 08:57
Ziopharm Oncology Stock Rises Amid Heavy Trading, Insider Purchases
MT Newswires · 09/07 16:15
MTCH, BILI and ZIOP among pre market gainers
RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborat...
Seekingalpha · 09/07 12:22
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at ...
Benzinga · 09/07 11:46
Insider Buy: Ziopharm Oncology
MT Newswires · 09/03 17:37
Ziopharm Oncology to Participate in September Investor Conferences
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual...
GlobeNewswire · 09/01 20:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZIOP. Analyze the recent business situations of ZIOPHARM Oncolgy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZIOP stock price target is 4.333 with a high estimate of 7.50 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 241
Institutional Holdings: 116.13M
% Owned: 53.87%
Shares Outstanding: 215.56M
TypeInstitutionsShares
Increased
48
2.82M
New
23
1.86M
Decreased
43
7.86M
Sold Out
19
1.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Executive Director
James Huang
Chief Executive Officer
Kevin Boyle
Chief Financial Officer
Timothy Cunningham
Executive Vice President/General Manager
Eleanor de Groot
Senior Vice President - Finance/Chief Accounting Officer/Treasurer
Kevin Lafond
Other
Raffaele Baffa
Director
Heidi Hagen
Independent Director
Christopher Bowden
Independent Director
Robert Postma
Independent Director
Mary Thistle
Independent Director
Jaime Vieser
Independent Director
Holger Weis
No Data
  • All
  • Financials
  • Insiders
More
About ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Webull offers kinds of ZIOPHARM Oncology Inc. stock information, including NASDAQ:ZIOP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZIOP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZIOP stock methods without spending real money on the virtual paper trading platform.